Lack of Efficacy

Lack of efficacy is a critical risk in pharmaceutical development, defined as the failure of a drug candidate to demonstrate a statistically significant and clinically meaningful therapeutic benefit in human clinical trials. According to retrospective analyses, it accounts for approximately 60% of all clinical trial terminations. International standards, particularly the ICH E9 Guideline "Statistical Principles for Clinical Trials," provide a framework for defining and assessing efficacy through pre-specified endpoints. In enterprise risk management, this is categorized as a primary technical and regulatory risk, distinct from toxicity risk, which concerns adverse effects. Failure to prove efficacy results in the denial of marketing authorization, leading to significant financial loss.

In enterprise risk management, mitigating efficacy risk involves a multi-stage approach. First, companies enhance preclinical validation using advanced models like AI/ML and organoids to improve candidate selection. Second, they implement robust clinical trial designs guided by ICH E9, defining clear endpoints and utilizing biomarkers. Adaptive trial designs are also used for flexibility. Third, a rigorous phase-gate review process establishes firm go/no-go decision points between trial phases. For example, AstraZeneca's "5R Framework" systematically addresses these factors, doubling its clinical success rate. The measurable outcome is an increased probability of success (POS) and a reduction in costly late-stage failures.

Taiwan's biotech enterprises face three key challenges. First is limited capital, restricting their ability to fund large, multi-national Phase III trials. The solution lies in strategic out-licensing partnerships or securing government grants. Second, there is a talent gap in personnel with global clinical development experience. This can be mitigated by outsourcing critical functions to specialized CROs and consultants. Third, designing a single trial protocol that satisfies multiple regulatory bodies (e.g., US FDA, EMA) is complex. The key is to engage in early regulatory consultation. The immediate priority is securing strategic partnerships to de-risk development and gain access to capital and expertise.

Winners Consulting specializes in lack of efficacy for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact